Chinese pharmaceutical company Beijing Tongrentang opened an office in Geneva.

Doris 2022-04-07


The latest member of Health Valley in Western Switzerland is one of the oldest, largest and most outstanding Chinese medicine companies.

Traditional Chinese medicine is not only a treasure of the Chinese people with its natural and comprehensive method, but also considered internationally to be helpful to the health and well-being of individuals and the overall development of the medical system. It is also supported by the World Health Organization (WHO), which supports the government in formulating and implementing policies aimed at integrating traditional medicine into modern healthcare.




Just in Geneva, the multicultural city where the World Health Organization is headquartered, the leading international Chinese medicine group Beijing Tongrentang decided to open its Swiss subsidiary. The company ’s general manager, Ding Yongling, said: “Geneva is a strategic location, and we look forward to establishing long-term partnerships with key partners in the region.” The new Swiss base will enable Beijing Tongrentang to promote Chinese medicine outside of China and is a western part of Switzerland Popular supplement for Health Valley. The fast-growing life sciences cluster extends from the Valais to Geneva and to Neuchatel and northern Bern. It has more than 900 companies and employs 25,000 highly skilled professionals.

Established in 1669, BeijingTongrentang is one of the oldest and most iconic Chinese medicine companies. It was originally the only company designated to supply medicines to the Royal Pharmacy. Today, it has grown into a modern international Chinese medicine group with approximately 15,000 employees in three business units (pharmaceuticals, retail and medical services).

The establishment of  Geneva is supported by the Greater Geneva Berne Region (GGBa) and the Geneva Economic Development, Research and Innovation Canton (DG DERI). This reflects the direct result of the bilateral free trade agreement that came into effect in 2014, which is the increasing interest of Chinese companies in the Swiss market.